CoChat

Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial

Open access
Jonasch, Eric, McCutcheon, Ian E, Gombos, Dan S, Ahrar, Kamran, Perrier, Nancy D, Liu, Diane, Robichaux, Christine C, Villarreal, Mercedes F, Weldon, Justin A, Woodson, Ashley H, Pilie, Patrick G, Fuller, Gregory N, Waguespack, Steven G, Matin, Surena F · 2018 · The Lancet Oncology
Cited by 103

The DOI matches its Crossref record.

Abstract

Background: No approved systemic therapy exists for von Hippel-Lindau disease, an autosomal dominant disorder with pleiotropic organ manifestations, including clear cell renal cell carcinomas, retinal, cerebellar and spinal hemangioblastomas, pheochromocytomas, pancreatic serous cystadenomas, and pancreatic neuroendocrine tumors. This prospective phase II study was designed to assess the efficacy and safety of pazopanib in patients with von Hippel-Lindau disease. Methods: Adult patients with clinical manifestations of von Hippel-Lindau disease were treated with pazopanib 800mg PO daily for 24 weeks, with an option to continue treatment if desired by patient and treating physician. Primary endpoints included objective response rate (ORR) and safety by intention to treat. ORR was measured both per patient and per lesion type. Radiographic assessments were performed at baseline and every 12 weeks using appropriate imaging modalities. Efficacy and safety were assessed using continuous monitoring and a Bayesian design. Study was registered as NCT01436227 in http://ClinicalTrials.gov. Trial accrual was complete at time of analysis. Findings: Thirty-one eligible patients were treated with pazopanib. The ORR was 42 percent. Organ specific response rate was 52 percent in renal cell carcinoma, 53 percent in pancreatic lesions, and 4 percent in central nervous system hemangioblastomas. The majority of patients chose to stay on treatment after 24 weeks. Four patients came off study because of grade-3/4 transaminitis, and three additional patients discontinued because of general treatment intolerance due to multiple intercurrent grade 1-2 toxicities. Treatment related serious adverse events included one case each of appendicitis and gastritis. One patient experienced a fatal central nervous system bleed. Interpretation: Pazopanib resulted in significant response rates in von HippelLindau disease, with an acceptable side effect profile. Pazopanib should be considered a treatment choice in patients with von Hippel-Lindau disease and growing lesions, or in patients with unresectable lesions where decrease in tumor size is desired.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(18)30487-x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 103

Metadata

Authors
Jonasch, E., McCutcheon, I. E., Gombos, D. S., Ahrar, K., Perrier, N. D., Liu, D., Robichaux, C. C., Villarreal, M. F., Weldon, J. A., Woodson, A. H., Pilie, P. G., Fuller, G. N., Waguespack, S. G., & Matin, S. F.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2018-10
Volume
19
Issue
10
Pages
1351-1359
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2889909012
Cited by
103
References
0
FWCI
5.58
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30487-x
The paper
Jonasch, E., McCutcheon, I. E., Gombos, D. S., Ahrar, K., Perrier, N. D., Liu, D., Robichaux, C. C., Villarreal, M. F., Weldon, J. A., Woodson, A. H., Pilie, P. G., Fuller, G. N., Waguespack, S. G., & Matin, S. F. (2018). Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30487-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.